
    
      The study will be prospective, double-blinded and randomized. The study will run for 12
      weeks. During the first 7 weeks there will be 2 groups in the study with subjects receiving a
      placebo or the study drug. During the last 4 weeks of the study, all subjects will be offered
      the study medication, pregabalin. The primary outcome measure will be pain relief documented
      by a 2-point change on the Likert pain scale with a secondary pain measure of sleep
      interruption.
    
  